Product Focus
You are here:
Esjay business strategy is of leadership in generic products, operational excellence and continuous improvement, with patient-centric product innovation.
With our Finished Dosage Form (FDF) business, Esjay is creating a greater impact on the quality of life for millions across the world. At the heart of our R&D efforts in this area is our FDF Development Center. The center brings together Formulation and Analytical Research, Clinical Pharmacodynamics and Pharmacokinetics, Regulatory Affairs, Packaging Development, Intellectual Property Management and Developmental QA functions.
Esjay has dedicated formulation research labs, laboratory-scale clinical supply facilities, and analytical research labs capable of developing different types of dosage forms
Our state-of-art oral finished dosage facility in Chennai, India conforms to international regulatory standards.
Generic medicines
Esjay Pharma will be the only such facility which can serve the regulated markets, with dosage forms manufacturing capacities like
- Oral Solid Dosages
- Topical Ointments
- Hard & Soft Gelatins
- Liquid Parenteral
- Oral Liquid Dosages
Product Will be updated soon....
Specialty therapeutic areas
Esjay pharma will cover the wide range of therapeutic areas focusing on opportunistic portfolio to serve the patients
Pain Management Portfolio
Neurodegenerative Disorders
Orphan Drugs
Pain Management Portfolio
Many patients suffer from severe headaches, and others endure debilitating pain, Esjay will be bringing specialty providing treatments for diseases of the central nervous and bringing innovative treatments to those suffering from migraine and headache, We also believe there is significant unmet need in chronic pain associated with osteoarthritis, and that new medicines are needed for appropriate patients.
Neurodegenerative Disorders
Neurodegenerative conditions and movement disorders such as multiple sclerosis (MS), Parkinson’s Disease (PD), Huntington’s Disease (HD) and Tardive Dyskinesia (TD) affect every aspect of life, with even the most mundane tasks requiring great courage and effort.
Orphan Drugs
Esjay Pharma will foray into research, development and marketing of treatments for rare diseases. Treatments for these diseases will be commercialized directly in USA Europe, the Middle East, Canada, Australia, Asian markets and in some Latin American countries, and through selected partners in a number of other countries